180 related articles for article (PubMed ID: 30266260)
21. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
Kizaki S; Hashimoto K; Matsui H; Usui H; Shozu M
Gynecol Oncol; 2015 Dec; 139(3):429-32. PubMed ID: 26456138
[TBL] [Abstract][Full Text] [Related]
22. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
[TBL] [Abstract][Full Text] [Related]
23. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
Harvey RA; Elias KM; Lim A; Bercow A; Short D; Horowitz NS; Berkowitz RS; Agarwal R; Seckl MJ
Curr Probl Cancer; 2021 Feb; 45(1):100622. PubMed ID: 32800689
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
[TBL] [Abstract][Full Text] [Related]
25. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
[No Abstract] [Full Text] [Related]
26. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
[TBL] [Abstract][Full Text] [Related]
27. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
[TBL] [Abstract][Full Text] [Related]
28. Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Berteloot P; Vergote I
Gynecol Oncol; 2012 Oct; 127(1):47-50. PubMed ID: 22705360
[TBL] [Abstract][Full Text] [Related]
29. Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study.
Frijstein MM; Lok C; van Trommel NE; Ten Kate-Booij MJ; Massuger L; van Werkhoven E; Short D; Aguiar X; Fisher RA; Kaur B; Sarwar N; Sebire NJ; Seckl MJ
BJOG; 2020 Feb; 127(3):389-395. PubMed ID: 31794098
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
31. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
[TBL] [Abstract][Full Text] [Related]
32. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
Li J; Li S; Yu H; Wang J; Xu C; Lu X
Gynecol Oncol; 2018 Feb; 148(2):247-253. PubMed ID: 29203174
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia.
Phianpiset R; Ruengkhachorn I; Kuljarusnont S; Jareemit N; Udompunturak S
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e495-e506. PubMed ID: 35253996
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
[TBL] [Abstract][Full Text] [Related]
37. Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies.
Hao J; Zhou W; Zhang M; Yu H; Zhang T; An R; Xue Y
BMC Cancer; 2021 Oct; 21(1):1122. PubMed ID: 34663255
[TBL] [Abstract][Full Text] [Related]
38. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
[TBL] [Abstract][Full Text] [Related]
39. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
[TBL] [Abstract][Full Text] [Related]
40. Factors related to treatment outcomes in low-risk gestational neoplasia.
Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
